Abstract
Radiofrequency (RF) ablation has gained great popularity in the treatment of Hepatocellular Carcinoma (HCC) on cirrhosis and is replacing Percutaneous Ethanol Injection (PEI) in treating 3cm or less HCC nodules. Its necrotic effect is more predictable than that of PEI and therefore RF can achieve a longer local tumor progression control and survival. In the last four years many data on its efficacy have been added in the Literature and long-term results on 3-5-year survival are available. In this review article data of the last 4 years on percutaneous RF ablation of HCC on cirrhosis are discussed in order to give an answer to questions put forward on this matter at 2000 EASL Barcelona Consensus Conference. Moreover, new perspectives in the percutaneous treatment of some form of advanced HCC (the so-called percutaneous thrombectomy) are presented together with some patents in the treatment of HCC.
Keywords: Cirrhosis, hepatocellular carcinoma, radiofrequency ablation, percutaneous interventional ultrasound
Recent Patents on Anti-Cancer Drug Discovery
Title: Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Volume: 5 Issue: 1
Author(s): Antonio Giorgio
Affiliation:
Keywords: Cirrhosis, hepatocellular carcinoma, radiofrequency ablation, percutaneous interventional ultrasound
Abstract: Radiofrequency (RF) ablation has gained great popularity in the treatment of Hepatocellular Carcinoma (HCC) on cirrhosis and is replacing Percutaneous Ethanol Injection (PEI) in treating 3cm or less HCC nodules. Its necrotic effect is more predictable than that of PEI and therefore RF can achieve a longer local tumor progression control and survival. In the last four years many data on its efficacy have been added in the Literature and long-term results on 3-5-year survival are available. In this review article data of the last 4 years on percutaneous RF ablation of HCC on cirrhosis are discussed in order to give an answer to questions put forward on this matter at 2000 EASL Barcelona Consensus Conference. Moreover, new perspectives in the percutaneous treatment of some form of advanced HCC (the so-called percutaneous thrombectomy) are presented together with some patents in the treatment of HCC.
Export Options
About this article
Cite this article as:
Giorgio Antonio, Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702226
DOI https://dx.doi.org/10.2174/157489210789702226 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Current Medicinal Chemistry Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Novel Dihydropyrimidinone-Derived Selenoesters as Potential Cytotoxic Agents to Human Hepatocellular Carcinoma: Molecular Docking and DNA Fragmentation
Anti-Cancer Agents in Medicinal Chemistry An Overview on Fibroblast Growth Factors: Structural, Functional and Therapeutic Implications
Current Proteomics Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry Fundamentals in Cardiovascular Imaging Technologies
Current Pharmaceutical Design Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Expression Profiles of MicroRNAs in Stem Cells Differentiation
Current Pharmaceutical Biotechnology Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach
Current Molecular Medicine Pancreatic Cancer Surgery: The State of the Art
Current Drug Targets Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg
Protein & Peptide Letters